ClinicalTrials.gg
Active, not recruitingNCT05323292Updated Jul 17, 2026

Vitamin A Status in Patients With Vocal Fold Leukoplakia

An observational study in Vitamin A, Vitamin A Deficiency and Leukoplakia, sponsored by University of Wisconsin, Madison. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by University of Wisconsin, Madison · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

This study will determine systemic vitamin A status and lesion histopathology of participants with vocal fold hyperkeratosis resulting in clinical leukoplakia.

Read the detailed description

The investigator's overarching goal is to determine if there is a pathophysiologic rationale for vitamin A supplementation in the treatment of vocal fold hyperkeratosis. Vocal fold hyperkeratosis is an accumulation of epithelial surface keratin resulting in clinical leukoplakia. It is primarily managed using destructive techniques that risk iatrogenic injury, fibrosis, and voice impairment. Given the potential morbidity of biopsy and lesion removal, there is a need for new approaches to the prevention and treatment of vocal fold leukoplakic disorders that are non-destructive. Vitamin A is a key regulator of epithelial health and systemic vitamin A deficiency could directly contribute to hyperkeratosis. Based on vitamin A's importance to vocal fold stellate and epithelial cell biology and its direct relevance to vocal fold hyperkeratosis, this study will assess vitamin A status in participants with vocal fold hyperkeratosis. An association would suggest further study on the effects of vitamin A optimization and/or supplementation in patients with leukoplakia, as well as an adjuvant therapy in participants for whom surgical treatment is indicated.

02

Conditions studied

  • Vitamin A
  • Vitamin A Deficiency
  • Leukoplakia
  • Vocal Cord Neoplasm
03

In context

Vitamin A Deficiency

67 studies on the registry are indexed under Vitamin A Deficiency; 7 are open to participants now.

This study's enrollment of 50 is below the median of 258 across 17 observational studies indexed under Vitamin A Deficiency.

Browse Vitamin A Deficiency studies →

Lead sponsor

University of Wisconsin, Madison is the lead sponsor of 1,188 studies on the registry; 181 are open to participants now.

Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Potential participants will be identified from the active caseloads of speech-language pathologists or otolaryngologists. During a routine clinical encounter, a member of the clinical team will inform potential participants of the research opportunity.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to provide .
  2. Willing to comply with all study procedures and be available for the duration of the study.
  3. Ability to take oral medication.
  4. At least 18 years of age.
  5. Leukoplakia study groups:

    1. Leukoplakia due to hyperkeratosis with dysplasia: -confirmed diagnosis of hyperkeratosis with dysplasia.
    2. Leukoplakia due to hyperkeratosis with no dysplasia: biopsy-confirmed diagnosis of hyperkeratosis with no dysplasia.
  6. Control group: Laryngoscopy showing no evidence of vocal fold epithelial disease.

Exclusion criteria

Exclusion Criteria:

  1. History of malignant vocal fold epithelial pathology.
  2. History of metabolic or liver disorder.
  3. History of anorexia or bulimia.
  4. Pregnant, lactating, or planning on becoming pregnant during the study period.
  5. History of >4.5 kg weight loss in the past 90 days.
  6. Medical or other inability to complete an 8 hour fast.
  7. Acute respiratory or gastrointestinal illness.
  8. Currently incarcerated.
  9. Impaired decision-making capacity.
  10. No or limited English speaking ability; illiterate or low-literacy ability.
  11. Profound visual or hearing impairment that limits written or verbal communication.
  12. Status relationship with a member of the study team.
  13. Not suitable for study participation due to other reasons at the discretion of the investigators.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
50 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Leukoplakia due to hyperkeratosis with dysplasia

    Biopsy-confirmed diagnosis of hyperkeratosis with dysplasia

  • Leukoplakia due to hyperkeratosis with no dysplasia

    Biopsy-confirmed diagnosis of hyperkeratosis with no dysplasia

  • Control group

    Laryngoscopy showing no evidence of vocal fold epithelial disease

06

What researchers measure

Primary outcomes

  1. Vitamin A liver reserves

    Total vitamin A liver concentration determined using retinol stable isotope dilution (μmol/g)

    Time frame: 14 days

Secondary outcomes

  1. Serum retinol

    Serum retinol concentration (μmol/L)

    Time frame: Baseline

  2. Serum retinyl esters

    Serum retinyl esters concentration (μmol/L)

    Time frame: Baseline

  3. Serum carotenoids

    Serum carotenoid concentrations (μmol/L)

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jun 2026, 48 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2022
First posted
Apr 12, 2022
StartActual
Jun 29, 2022
Primary completionActual
Jun 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05323292
Responsible party
Sponsor
First posted
Apr 12, 2022
Start date
Jun 29, 2022
Primary completion
Jun 30, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Jul 17, 2026

Study contacts

Nathan Welham, PhD, CCC-SLP
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion